Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. on January 25, 2019, regarding events occurring on January 24, 2019. The filing addresses Item 5.02, detailing the approval of executive compensation adjustments and equity grants by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2019 Base Salaries Approved:
- Nassim Usman, Ph.D. (President & CEO): $528,900
- Fletcher Payne (CFO): $379,200
- Howard Levy, M.B.B.Ch., Ph.D., M.M.M. (CMO): $419,500
- 2018 Performance Bonuses Approved:
- Nassim Usman, Ph.D.: $240,400
- Fletcher Payne: $120,855
- Howard Levy, M.B.B.Ch., Ph.D., M.M.M.: $139,230
- Stock Option Grants:
- Nassim Usman: 80,000 shares
- Fletcher Payne: 38,000 shares
- Howard Levy: 35,000 shares
- Terms: Exercise price of $7.97 per share; vesting in equal monthly installments over four years commencing January 24, 2019.
Material Changes
The filing reports the formal approval of specific salary increases and bonus payments for fiscal year 2019 and 2018, respectively, as well as new equity incentives. No comparative financial data or prior period compensation figures are provided in this text to quantify the magnitude of change.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is strictly a disclosure of executive compensation actions.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2018 Omnibus Incentive Plan to assess the impact of the 153,000 new option grants.
- Confirm the company's cash position to ensure it can fund the approved 2018 bonuses totaling approximately $500,485.
- Review the company's most recent 10-K or 10-Q to compare the approved 2019 base salaries against prior year compensation.
- Note the discrepancy between the metadata company name ("Gyre Therapeutics") and the filing registrant ("Catalyst Biosciences, Inc."); verify the correct entity for investment analysis.